Lurbinectedin +/- Irinotecan for Small Cell Lung Cancer
Trial Summary
What is the purpose of this trial?
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you need to stop your current medications. However, you must have at least three weeks since your last antineoplastic treatment and recover from any adverse events to grade ≤ 1. It's best to discuss your current medications with the trial team.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, you must have at least three weeks since your last cancer treatment and recover from any side effects before starting the trial.
What data supports the idea that Lurbinectedin +/- Irinotecan for Small Cell Lung Cancer is an effective drug?
The available research shows that Irinotecan, when combined with another drug called cisplatin, significantly improved the survival of patients with extensive small-cell lung cancer compared to the standard treatment. Specifically, patients lived longer without the cancer getting worse, with a median time of 6.9 months compared to 4.8 months for the standard treatment. This suggests that Irinotecan, especially when used in combination with other drugs, can be an effective option for treating small-cell lung cancer.12345
What data supports the effectiveness of the drug Lurbinectedin +/- Irinotecan for Small Cell Lung Cancer?
What safety data exists for Lurbinectedin and Irinotecan in treating small cell lung cancer?
Irinotecan (also known as CPT-11 or Camptosar) has been studied extensively in small cell lung cancer (SCLC) and other cancers. It has shown significant activity and is often used in combination with other drugs like cisplatin and etoposide. Studies have demonstrated its effectiveness and tolerability, with some trials indicating improved survival rates when combined with cisplatin. Lurbinectedin, approved for metastatic SCLC, has an acceptable and manageable safety profile at the approved dose of 3.2 mg/m2 every 3 weeks, as shown in a phase II basket trial involving 105 adult SCLC patients. Overall, both drugs have been evaluated for safety and efficacy in SCLC, with manageable side effects when used at recommended doses.13678
Is the combination of Lurbinectedin and Irinotecan safe for treating small cell lung cancer?
Lurbinectedin has been approved for treating small cell lung cancer and was found to have an acceptable and manageable safety profile in patients. Irinotecan, when used in combination with other drugs like cisplatin, has been generally well-tolerated in patients with small cell lung cancer, showing significant antitumor activity.13678
Is the drug Irinotecan a promising treatment for small cell lung cancer?
What makes the drug Lurbinectedin +/- Irinotecan unique for small cell lung cancer?
Lurbinectedin combined with Irinotecan is unique because it explores a novel combination of drugs that may offer a new approach to treating small cell lung cancer, potentially improving outcomes compared to standard treatments. Irinotecan has shown significant activity in small cell lung cancer and has been effective in combination with other drugs, suggesting that this new combination could provide additional benefits.12368
Eligibility Criteria
Adults with small-cell lung cancer who've had one prior platinum-based chemotherapy can join this trial. They must have good organ function, no recent serious heart issues or uncontrolled infections, and cannot be pregnant or breastfeeding. Participants need to agree to use effective contraception and should not have been treated with certain drugs like lurbinectedin before.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either lurbinectedin as a single agent, lurbinectedin in combination with irinotecan, or investigator's choice of topotecan or irinotecan
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Irinotecan
- Lurbinectedin
- Topotecan
Irinotecan is already approved in United States, European Union, Japan, Canada for the following indications:
- Colorectal cancer
- Colorectal cancer
- Colorectal cancer
- Small cell lung cancer
- Colorectal cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
PharmaMar
Lead Sponsor
José María Fernández de Sousa-Faro
PharmaMar
Chief Executive Officer since 1986
PhD in Biochemistry, Complutense University of Madrid
Carmen Cuevas Marchante
PharmaMar
Chief Medical Officer since 2002
MD, University of Navarra